120 related articles for article (PubMed ID: 30023090)
41. Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.
Klikovits T; Hoda MA; Dong Y; Arns M; Baumgartner B; Errhalt P; Geltner C; Machan B; Pohl W; Hutter J; Eckmayr J; Studnicka M; Flicker M; Cerkl P; Kirchbacher K; Klepetko W
Wien Klin Wochenschr; 2016 Sep; 128(17-18):627-34. PubMed ID: 27457873
[TBL] [Abstract][Full Text] [Related]
42. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
43. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
44. Malignant pleural mesothelioma: an update on biomarkers and treatment.
Ray M; Kindler HL
Chest; 2009 Sep; 136(3):888-896. PubMed ID: 19736192
[TBL] [Abstract][Full Text] [Related]
45. Commentary: Moving beyond phenotypic diagnosis.
Stansfield WE
JTCVS Tech; 2021 Apr; 6():44-45. PubMed ID: 34318137
[No Abstract] [Full Text] [Related]
46. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
47. Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.
Salazar C; Kanter Md N; Abboud A
Cureus; 2018 Jun; 10(6):e2749. PubMed ID: 30109162
[TBL] [Abstract][Full Text] [Related]
48. Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
Arulananda S; Thapa B; Walkiewicz M; Zapparoli GV; Williams DS; Dobrovic A; John T
J Thorac Oncol; 2018 Oct; 13(10):1588-1594. PubMed ID: 30056163
[TBL] [Abstract][Full Text] [Related]
49. Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment.
Szolkowska M; Blasinska-Przerwa K; Knetki-Wroblewska M; Rudzinski P; Langfort R
J Thorac Dis; 2018 Jun; 10(Suppl 17):S1966-S1970. PubMed ID: 30023092
[No Abstract] [Full Text] [Related]
50. Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Dessanti P; Roncella S
Oncol Lett; 2021 Feb; 21(2):128. PubMed ID: 33552249
[TBL] [Abstract][Full Text] [Related]
51. Malignant pleural mesothelioma: a population-based study of survival.
Milano MT; Zhang H
J Thorac Oncol; 2010 Nov; 5(11):1841-8. PubMed ID: 20975379
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of histologic subtyping of malignant pleural mesothelioma.
Brcic L; Kern I
Transl Lung Cancer Res; 2020 Jun; 9(3):924-933. PubMed ID: 32676358
[TBL] [Abstract][Full Text] [Related]
53. Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?
Røe OD
J Thorac Dis; 2018 Jun; 10(Suppl 17):S1956-S1961. PubMed ID: 30023090
[No Abstract] [Full Text] [Related]
54. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
55. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
Antman K; Shemin R; Ryan L; Klegar K; Osteen R; Herman T; Lederman G; Corson J
J Clin Oncol; 1988 Jan; 6(1):147-53. PubMed ID: 3335886
[TBL] [Abstract][Full Text] [Related]
56. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
